| 新型冠状病毒肺炎合并肥胖症的评估与治疗策略 |
| |
| 引用本文： | 王诗蕊,陈适,朱惠娟.新型冠状病毒肺炎合并肥胖症的评估与治疗策略[J].协和医学杂志,2021,12(1):13-17. |
| |
| 作者姓名： | 王诗蕊 陈适 朱惠娟 |
| |
| 作者单位： | 1.中国医学科学院 北京协和医学院临床医学八年制，北京 100730 |
| |
| 基金项目： | 中国医学科学院医学与健康科技创新工程2016-I2M-1-002 |
| |
| 摘 要： | 新型冠状病毒肺炎(coronavirus disease 2019，COVID-19)已成为危及全球的传染性疾病，重症患者死亡风险极高。临床研究显示，肥胖症是COVID-19患者发生重症及死亡的独立危险因素。对于合并肥胖症的COVID-19患者，应尽早评估肥胖相关合并症，并在营养、气道管理、抗凝、合并症控制等方面采取更积极的干预措施，以改善预后。
|
| 关 键 词： | 新型冠状病毒肺炎 肥胖症 评估 治疗 |
| 收稿时间： | 2020-09-03 |
Evaluation and Treatment of Coronavirus Disease 2019 with Obesity |
| |
| Institution: | 1.Eight-year Program of Clinical Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China2.Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China |
| |
| Abstract: | The pandemic of coronavirus disease 2019 (COVID-19) has spread worldwide and the mortality is high in severe COVID-19 patients. Clinical studies suggested that obesity is an independent risk factor for severe and dead cases of COVID-19. For COVID-19 patients with obesity, early evaluation of obesity-related comorbidities and aggressive treatments, including diet control, airway management, anticoagulant thromboprophylaxis, and management of comorbidities, are encouraged to improve their prognosis. |
| |
| Keywords: | |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《协和医学杂志》浏览原始摘要信息 |
| 点击此处可从《协和医学杂志》下载免费的PDF全文 |
|
